CGC Product launch

Canopy Growth Expands Global Medical Portfolio with Launch of 7ACRES in Australia

Published August 05, 2025 at 11:30 AM

SMITHS FALLS, Ontario--(BUSINESS WIRE)--Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (Nasdaq: CGC), a world-leading cannabis company dedicated to unleashing the power of cannabis to improve lives, has introduced its Canadian-grown 7ACRES brand in Australia, expanding the Company’s medical cannabis offering with two high-THC sativa strains: Ultra Jack and Jack Frost. Ultra Jack, a cross of Ultra Sour and Jack Haze, is one of 7ACRES’ top performing flower strains in th

Related Questions

How will the launch of 7ACRES in Australia affect Canopy Growth's revenue growth and earnings guidance? How might this expansion influence investor sentiment and the stock’s valuation multiples relative to peers? How will the new offering impact Canopy’s overall product mix, inventory turnover, and cash flow? What is the expected market size and growth potential for medical cannabis in Australia, and how much market share can Canopy capture? What is the expected timeline for revenue generation from the Australian market and when will it be reflected in financial reporting? What are the regulatory hurdles and compliance costs associated with expanding into the Australian medical cannabis market? What are the anticipated pricing and margin implications of selling high‑THC medical cannabis in Australia? How does the introduction of two high‑THC sativa strains (Ultra Jack and Jack Frost) fit into Canopy’s product portfolio and margin profile? How does this expansion compare to recent product launches by competitors such as Tilray, Cronos, and Curaleaf in the same region? Will the Australian launch drive incremental demand for Canopy’s Canadian‑grown product supply and logistics?